Medipal Holdings (7459) · RiskDropped
Suspected Antimonopoly Act Violations and Inspection Concerning MP Agro’s Animal Drug Bids
First written in FY2025-H1. 1 of 2 entries say "Dropped", first in FY2026. Latest entry: FY2026.
2entries
3years
0from disclosures
How it moved
Same theme, other companies
Antimonopoly Act on-site inspection concerning MPアグロ's veterinary pharmaceutical bidsA theme 2 companies write about · 2 as a headwind · 0 as a tailwind
0 other companies' latest entry also says "Dropped".
Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Full recordFilings, disclosures and news, newest first
- FY2026DroppedAnnual reportIn “Business and Other Risks” for FY2026, no standalone disclosure was identified concerning the suspected Antimonopoly Act violation by MPアグロ and the Japan Fair Trade Commission inspection disclosed in FY2025-H1.
- FY2025-H1First statedAnnual report
「ＭＰアグロ株式会社 (Kita-Hiroshima, Hokkaido), a wholly owned consolidated subsidiary of the Company, was subject to an on-site inspection by the Japan Fair Trade Commission in October 2024 on suspicion of violating the Antimonopoly Act in connection with bids for veterinary pharmaceuticals ordered by Yamagata Prefecture and other parties.」
The Company disclosed for the first time that ＭＰアグロ had been subject to an on-site inspection by the Japan Fair Trade Commission in October 2024 in connection with bids for veterinary pharmaceuticals ordered by Yamagata Prefecture and other parties. The disclosure does not establish a violation and refers only to a “suspicion.”